Dehydrocorydaline |
Catalog No.GN10040
One-Click Copy Product Info
|
Dehydrocorydaline is one of the quaternary ammonium alkaloids from Corydalis Rhizoma.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 30045-16-0
Sample solution is provided at 25 µL, 10mM.
Dehydrocorydaline is one of the quaternary ammonium alkaloids from Corydalis Rhizoma[1]. Dehydrocorydaline inhibits platelet aggregation by a mechanism involving the adenosine diphosphate (ADP)-receptors P2Y1 and P2Y12, and it can also alter the content of monoamine in brains by limiting uptake-2 monoamine transporters, thus exerting its antidepressant effects[1-2]. Dehydrocorydaline exhibited potent anti-malarial activity (IC50=38nM) when tested against the P. falciparum 3D7 strain[3].
In vitro, MCF-7 cells were treated with Dehydrocorydaline (0-200μM) for 24 hours, which significantly inhibited the growth of MCF-7 cells in a dose-dependent manner. When MCF-7 cells were co-incubated with 200μM Dehydrocorydaline and 10μM Z-IETD-FMK, the cell death induced by Dehydrocorydaline could be abrogated[4]. Treatment of C2C12 myoblasts with Dehydrocorydaline (125-500nM; 2 days) increased the expression levels of muscle‑specific proteins, including MyoD, myogenin, and myosin heavy chain in a dose-dependent manner[5].
In vivo, after intraperitoneal injection of Dehydrocorydaline (3.6, 6, or 10mg/kg), the onset time of writhing in mice was delayed in a dose-dependent manner in the acetic acid-induced test, and a dose-dependent antinociceptive effect was observed[6]. Subcutaneous injection of 500µM Dehydrocorydaline (50µL) into mice with subcutaneously implanted MDA-MB-231 cells inhibited the growth of MDA-MB-231 tumor xenografts in SCID mice and decreased cell proliferation in newly formed tumors in vivo[7].
References:
[1] Jin L, Zhou S, Zhu S, et al. Dehydrocorydaline induced antidepressant-like effect in a chronic unpredictable mild stress mouse model via inhibiting uptake-2 monoamine transporters. Eur J Pharmacol. 2019;864:172725.
[2] Li Y, Zhang L, Zhang P, Hao Z. Dehydrocorydaline Protects Against Sepsis-Induced Myocardial Injury Through Modulating the TRAF6/NF-κB Pathway. Front Pharmacol. 2021;12:709604.
[3] Nonaka M, Murata Y, Takano R, Han Y, Kabir MHB, Kato K. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018;17(1):244.
[4] Xu Z, Chen X, Fu S, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells [published correction appears in Am J Chin Med. 2012;40(6):1323]. Am J Chin Med. 2012;40(1):177-185.
[5] Yoo M, Lee SJ, Kim YK, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016;14(4):3029-3036.
[6] Yin ZY, Li L, Chu SS, Sun Q, Ma ZL, Gu XP. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016;6:27129.
[7] Huang Y, Huang H, Wang S, Chen F, Zheng G. Dehydrocorydaline inhibits the tumorigenesis of breast cancer MDA‑MB‑231 cells. Mol Med Rep. 2020;22(1):43-50.
| Cell experiment [1]: | |
|
Cell lines |
MCF-7 cell |
|
Preparation Method |
The effect of Dehydrocorydaline on MCF-7 cell proliferation was determined by MTT assay. MCF-7 cells (1x104cells/well) were seeded in 96-well plates and treated with different concentrations of Dehydrocorydaline (0-200μM) for 24h. The cell viability was determined. To explore the role of caspase-8 in Dehydrocorydaline induced cytotoxicity, a caspase-8 inhibitor Z-IETD-FMK (10μM) was co-incubated with 200μM Dehydrocorydaline. |
|
Reaction Conditions |
0μM, 50μM, 100μM, 200μM; 24h |
|
Applications |
Dehydrocorydaline treatment significantly inhibited the growth of MCF-7 cells in a dose-dependent manner. The cell viability was decreased by approximately 40% after 24h of 200μM Dehydrocorydaline. Dehydrocorydaline-induced cell death could be abrogated by Z-IETD-FMK co-incubation. |
| Animal experiment [2]: | |
|
Animal models |
Mice |
|
Preparation Method |
The mice were first habituated to a plastic observation chamber for 60 minutes. Then, the mice were given vehicle, Dehydrocorydaline (3.6, 6, or 10mg/kg, i.p.) 15min before the test. Subsequently, the mice were treated i.p. with 1% acetic acid (10ml/kg). The time of the onset of the writhing was recorded, and the number of writhing episodes in each 5min in the 30min period beginning at the time of the acetic acid administration was counted. Writhing was marked by contraction of the abdomen and extension of the trunk and hind limbs. The percentage inhibition of writhing was calculated. |
|
Dosage form |
3.6, 6, or 10mg/kg; i.p. |
|
Applications |
After intraperitoneal injection of Dehydrocorydaline, the onset time of writhing in mice was delayed in the acetic acid-induced test, and a dose-dependent antinociceptive effect was observed. |
|
References: |
|
| Cas No. | 30045-16-0 | SDF | |
| Chemical Name | 2,3,9,10-tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium | ||
| Canonical SMILES | CC1=C2C=CC(=C(C2=C[N+]3=C1C4=CC(=C(C=C4CC3)OC)OC)OC)OC | ||
| Formula | C22H24NO4 | M.Wt | 366.44 |
| Solubility | ≥ 13.2mg/mL in DMSO | Storage | Stored at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.729 mL | 13.6448 mL | 27.2896 mL |
| 5 mM | 545.8 μL | 2.729 mL | 5.4579 mL |
| 10 mM | 272.9 μL | 1.3645 mL | 2.729 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)